Objective: This study aims to assess the efficacy and safety of sunitinib in Japanese patients with metastatic renal cell carcinoma (RCC). Methods: Fifty-one Japanese patients with prior nephrectomy, 25 treatment-naive patients (first-line group) and 26 cytokine-refractory patients ( pretreated group) were enrolled in this phase II trial. Patients received sunitinib 50 mg orally, once daily, in repeated 6-week cycles (4 weeks on treatment, 2 weeks off). The primary endpoint was RECISTdefined objective response rate (ORR) with tumour assessments every 6 weeks via computed tomography or magnetic resonance imaging. Toxicity was assessed regularly. In the primary efficacy analysis of the intent-to-treat (ITT) population, ORR and 95% confidence interval were calculated based on independent review. Secondary time-to-event endpoints, such as progression-free survival (PFS), were estimated using the KaplanMeier method. Results: In the ITT population, ORR was 48.0% in the first-line group (after a median 4 cycles), 46.2% in the pretreated group (5 cycles) and 47.1% overall, with median times to tumour response of 7.1, 10.7 and 10.0 weeks, respectively. Median PFS was 46.0, 33.6 and 46.0 weeks, respectively. The most common treatment-related grade 3/4 adverse events and laboratory abnormalities were fatigue (20%), hand-foot syndrome (14%) and hypertension (12%), decreased platelet count (55%), decreased neutrophil count (51%), increased lipase (39%) and decreased lymphocyte count (33%). Conclusions: In Japanese patients with RCC, sunitinib is consistently effective and tolerable with similar risk/benefit as that in Western patients, though there was a trend toward greater antitumour efficacy and higher incidence of haematological adverse events in Japanese patients.
INTRODUCTION
Renal cell carcinoma (RCC) accounts for approximately 2 -3% of all cancers (1,2) and 80 -85% of cases of malignant kidney disease (1) . The global incidence of RCC is increasing (3) , with the highest rates in North America and Scandinavia (4) . In Japan, there were an estimated 7400 persons diagnosed with RCC in 2002, up from 6360 persons in 1997, with crude incidence rates of 8.2 men and 3.6 women per 100 000 people (5) .
Up to 30% of patients present with metastatic disease (6, 7) , and approximately 40% of patients treated for localized RCC eventually relapse (6, 8) . Until recently, cytokine therapy with interferon-alpha (IFN-a) and/or interleukin-2 (IL-2) had provided the mainstay of systemic RCC treatment, but with limited success and high corresponding rates of adverse events (9, 10) . More recently, increased understanding of RCC biology has led to the development of targeted agents that block proliferative, dysregulated tumour pathways and have demonstrated superior efficacy over cytokines and changed the RCC treatment paradigm (11, 12) .
Sunitinib malate (SUTENT w , Pfizer Inc., New York, NY, USA) is an oral, multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1 -3 and platelet-derived growth factor receptors a and b (13) . Single-agent sunitinib showed unprecedented antitumour activity in two consecutive single-arm phase II trials of patients with cytokine-refractory metastatic RCC (14 -16) , demonstrating an objective response rate (ORR) of 33% (per independent, third-party, core imaging laboratory review), a median time to tumour progression (TTP) of 10.7 months, and a median overall survival (OS) of 23.9 months (as recently reported for the second phase II trial) (16) . In addition, sunitinib subsequently demonstrated superior firstline efficacy over IFN-a, with significantly greater progression-free survival (PFS) and ORR (11 vs. 5 months and 47% vs. 12%, respectively; both P , 0.001) in an international, randomized phase III trial of 750 patients with metastatic RCC (17) . Median OS was greater in the sunitinib group (26.4 months) vs. the IFN-a group (21.8 
months).
These data have established sunitinib monotherapy as a standard of care for RCC treatment. Sunitinib is now approved multinationally for the treatment of first-and second-line advanced RCC. Here, we report the efficacy and safety results of the first Japanese phase II study of single-agent sunitinib in both treatment-naïve and cytokinepretreated Japanese patients with metastatic RCC.
PATIENTS AND METHODS

PATIENT POPULATION
The study population comprised patients aged 20 years with histologically proven RCC, with a clear-cell component and metastases; evidence of unidimensionally measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) (18) and prior nephrectomy. Other inclusion criteria included: Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1; resolution of all acute toxic effects of prior therapy to 1 severity (classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 3.0); and adequate organ function. Patients with the following were excluded: any prior systemic treatment since RCC diagnosis (first-line population); any prior systemic therapy other than one cytokine-based regimen that could include multiple cytokines ( pretreated population); prior treatment within 4 weeks of the start of study treatment; any secondary malignancy within the previous 5 years; uncontrolled hypertension; history of/known brain metastases; and cardiovascular disease. All patients gave written informed consent. This study was approved by the institutional review board at each participating centre and was conducted in accordance with the International Conference on Harmonization Guideline for Good Clinical Practice.
STUDY DESIGN
This was a multicentre, open-label, non-randomized, singlearm, phase II study of sunitinib. Sunitinib was selfadministered at a starting dose of 50 mg orally, once daily, in the morning, without regard to meals, in repeated 6-week cycles according to Schedule 4/2 (4 weeks on treatment followed by 2 weeks off).
Patients were monitored for toxicity, and doses were adjusted according to individual patient tolerance according to the protocol. Doses were reduced to 37.5 mg/day in cases of treatment-related grade 3 adverse events, and by an additional 12.5 mg/day if toxicities persisted to a minimum dose of 25 mg/day. Treatment was continued until one of the following occurred: disease progression; requirement for additional anticancer treatment; development of left ventricular systolic dysfunction; or treatment withdrawal.
STUDY ASSESSMENTS
Patients were screened within 21 days prior to treatment initiation. Baseline evaluations included physical examination; ECOG PS; haematology; biochemistry; tumour assessment (scanned by computed tomography [CT] or magnetic resonance imaging [MRI]); 12-lead electrocardiography; and echocardiography or MUGA scan.
The primary efficacy endpoint was ORR, defined as the proportion of patients with a confirmed complete response (CR) or partial response (PR) according to RECIST (18) . Tumour assessments were obtained every 6 weeks by investigators via CT or MRI scan with or without X-ray with response confirmed by an Extramural Review Committee (independent review). Secondary endpoints included PFS, TTP, duration of response, time to tumour response, and OS.
Safety and tolerability were assessed at regular intervals with adverse event monitoring, using NCI CTCAE version 3.0 Jpn J Clin Oncol 2010;40 (3) 195 to document adverse events and classify severity; haematology and biochemistry; body weight; vital signs; ECOG PS; 12-lead electrocardiography; and echocardiography or MUGA scan.
Health-related quality of life was assessed using two measures from the EuroQol Group's EQ-5D self-report questionnaire, a population preference-based health state utility score (EQ-5D Index) and a visual analogue scale (EQ-VAS) for assessing a patient's overall health state (19) (20) (21) . Trough plasma concentrations of sunitinib, its active metabolite (SU12662) and total drug (sunitinib þ SU12662) were assessed. Plasma samples for pharmacokinetic (PK) analysis were collected prior to treatment on days 1, 14 and 28 of cycle 1, days 1 and 28 of cycle 2, and day 28 of cycle 3.
STATISTICAL METHODS
In the primary efficacy analysis of the intent-to-treat (ITT) population, the ORR and 95% confidence interval (CI) were calculated for the first-line and pretreated populations based on independent review (the same analysis was performed for investigators' assessments). Sample sizes were calculated based on response rates for each population in which it was concluded that efficacy was confirmed if the lower limit of the 95% CI was greater than or equal to the threshold rate in each population. The thresholds were set at levels considered to be clinically ineffective for each population (5% for the pretreated population and 10% for the first-line population). Based on these assumptions, sample sizes of 26 and 25 patients were required for the pretreated and first-line populations, respectively, to provide a power of 80% with an alpha level of 2.5%. In the analysis of secondary endpoints, PFS, TTP and OS assessed by investigators were summarized using the Kaplan -Meier method (22) . In the PK analysis, descriptive statistics were calculated for trough plasma concentrations of sunitinib, SU12662 and total drug.
RESULTS
PATIENTS
As of February 2007 (time of data cutoff), 51 patients were enrolled at 12 sites in Japan and had completed at least four cycles of sunitinib treatment. The mean age was 56.6 years (range: 33 -76) in the first-line population (n ¼ 25) and 61.1 years (range: 34 -77) in the pretreated population (n ¼ 26). All patients had an ECOG PS of 0 -1 at baseline. The most prevalent site of metastasis was the lung (82%). Baseline characteristics are summarized in Table 1 .
In the second-line population, 22 patients (85%) had received previous treatment with IFN-a. The best responses to previous treatment were CR in one patient (4%) and PR in 11 patients (42%); 13 patients (50%) exhibited progressive disease. Cytokine-based treatment was discontinued because of tumour progression in 22 patients (85%), intolerance in two patients (8%) and other reasons in two patients (8%). Prior cytokine-based therapy, n (%)
ECOG PS, Eastern Cooperative Oncology Group performance status; IFN, interferon; IL, interleukin.
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TREATMENT AND DISPOSITION
At the time of analysis, patients in the first-line population had received a median of four cycles of treatment (range: 1 -8) and patients in the pretreated population had received five cycles (range: 1 -7). Eleven patients (44%) in the firstline population and nine patients (35%) in the pretreated population discontinued treatment. One patient in the pretreated population died due to tumour progression, which was considered unrelated to treatment. Sunitinib treatment and disposition by patient population are summarized in Table 2 .
EFFICACY
Based on independent review, ORR in the ITT populations was 48.0% (95% CI, 27.8 -68.7) in the first-line population, 46.2% (95% CI: 26.6 -66.6) in the pretreated population and 47.1% (95% CI: 32.9 -61.5) in the overall population (Table 3) . Identical ORR values were reported by the investigators. The lower confidence limit for ORR exceeded the threshold value for each population (10% for the first-line population and 5% for the pretreated population). Twelve patients in each population achieved a confirmed PR according to investigator assessment; one patient achieved a confirmed CR (and 11 patients achieved a confirmed PR) in the first-line population based on independent review (Table 3) . Median time to tumour response based on independent review was 7.1 weeks (95% CI: 4.0 -10.1) in the first-line population, 10.7 weeks (95% CI: 4.0 -16.0) in the pretreated population and 10.0 weeks (95% CI: 4.0 -11.0) in the overall population, with similar data reported by the investigators (data not shown).
Progressive disease during treatment with sunitinib (including 28 days after the completion of treatment) was documented by investigators in eight patients in both the first-line and pretreated populations (32% and 31%, respectively) including three patients who had PR on study, one patient and two patients, respectively. Of these three patients with PR, duration of response was 42.3 weeks for the firstline patient and 21.0 and 30.0 weeks for the pretreated patients.
Median PFS was 46.0 (95% CI: 46.0 -NR), 33.6 (95% CI: 25.0 -NR) and 46.0 (95% CI: 28.4 -NR) weeks in the firstline, pretreated and overall populations, respectively ( Figure 1 ; overall population not shown); PFS and TTP were identical. At the time of analysis, median OS had not been reached in either population.
SAFETY
All 51 patients experienced treatment-related adverse events, the majority of which were grade 1 or 2 in severity ( Table 4 ). The most commonly reported treatment-related adverse events in the first-line population were anorexia (68%), skin discoloration (64%), diarrhoea (60%) and pyrexia (60%). In the pretreated population, the most commonly reported adverse events were skin discoloration (81%), fatigue (69%), anorexia (54%), dysgeusia (54%) and rash (54%).
The most common grade 3 adverse events in the first-line population were diarrhoea and hand-foot syndrome, each of which occurred in four patients (16%) and were manageable and reversible; the most common grade 3 adverse event in the pretreated population was fatigue, occurring in six patients (23%). No grade 4 or 5 treatment-related adverse events were reported in the first-line population, and in the pretreated population, one patient experienced grade 4 fatigue; however, this patient recovered and continued study treatment.
The most frequently reported laboratory abnormalities in the first-line population included decreased platelet count (96% of patients), white blood cells (84%), lymphocytes (84%) and neutrophils (72%), as well as increased lactate dehydrogenase (68%), aspartate aminotransferase (56%), lipase (60%), creatinine (56%) and alanine aminotransferase (52%; Table 4 ). Similar laboratory abnormalities were reported in the pretreated population, all occurring in .50% of patients except for increased creatinine, which occurred in 38%.
In the first-line population, the most common grade 3 laboratory abnormality was decreased platelet count, occurring in 12 patients (48%); the most common grade 4 abnormality was increased lipase, occurring in three patients (12%). In the pretreated population, grade 3 decreased neutrophils and platelets occurred in 15 (58%) and 12 patients (46%), respectively. No grade 5 laboratory abnormalities occurred in either patient population. Treatment changes (dose reductions, interruptions and/or extensions of off-treatment periods) owing to treatment-related adverse events were reported in 40 patients (78%); overall, 17 patients (68%) in the first-line population, and 23 patients (88%) in the pretreated population. Treatment changes owing to decreased platelet counts were reported in approximately 50% of patients.
QT-corrected interval prolongation occurred in two patients (4%) overall, but was not clinically significant and resolved without treatment changes. Reduced left ventricular ejection fraction (LVEF) was reported as a serious adverse event in one patient, but abated after treatment discontinuation.
Five patients (20%) in the first-line population and four patients (15%) in the pretreated population experienced treatment-related adverse events that led to discontinuation. The adverse events most commonly leading to discontinuation were hypertension and decreased LVEF, each reported in two patients (4%) overall. No discontinuations owing to haematological or biochemical laboratory abnormalities were reported.
HEALTH-RELATED QUALITY OF LIFE
For the EQ-5D index score (data not shown), the range of mean change at each endpoint from baseline was from 20.1573 to 0.0375 in the first-line population and from 20.0974 to 0.0513 in the pretreated population. For EQ-VAS score (Figure 2 ), the range of mean change at each endpoint from baseline was from 212.35 to 2.71 in the firstline population and from 211.82 to 4.17 in the pretreated population. Both scores tended to decline during treatment with sunitinib and subsequently recovered during the offtreatment periods in both populations.
PHARMACOKINETICS
Median trough plasma concentrations of total drug reached therapeutic levels (.50 ng/ml) (23) on day 14 of cycle 1 in both populations, and levels were sustained throughout treatment during the dosing periods without clinically relevant differences in concentrations between populations. Median trough plasma concentrations of total drug on days 14 and 28 of cycle 1 were comparable to those observed on day 28 of cycles 2 and 3 ( Figure 3) .
Potential associations between body weight and systemic exposure (area under the plasma-concentration curve; AUC) to sunitinib, SU12662 and total drug were explored in Japanese and Caucasian subjects (Figure 4 ). The population for this analysis comprised 13 Western studies, one of which included Japanese subjects, and a Japanese study (25) . No clear correlations between weight and exposure were observed in either population.
DISCUSSION
Results from this open-label, multicentre phase II trial demonstrated that sunitinib 50 mg, self-administered orally 198 Sunitinib in Japanese patients with metastatic RCC Jpn J Clin Oncol 2010;40(3) 199 on Schedule 4/2, was effective and well-tolerated for the first-and second-line treatment of metastatic RCC in Japanese patients. This is the first such study of this magnitude of patients in Japan. Data revealed similar ORRs in the two patient populations, 48.0% and 46.0% in the first-line and pretreated patients, respectively, with identical findings reported by investigator and independent reviewers. Although cross-study comparisons should be interpreted with care owing to differences in methodology, these results compare favourably with those from previous, larger trials of sunitinib in treatment-naïve (47%) (17) and cytokine-refractory patients (33%) (14 -16) with metastatic RCC, as well as with the ORR of 12.4% recently reported for sorafenib in a phase II study of Japanese patients with cytokine-refractory metastatic RCC (24) . In addition, as reported in previous trials (14 -17) , sunitinib was associated with substantially longer PFS in the first-line population compared with the pretreated population (46.0 vs. 33.6 weeks, respectively).
All patients experienced treatment-related adverse events, the majority of which were grade 1 or 2 in severity. Most patients were able to resume therapy following treatment changes, with only five patients (20%) in the first-line population and four patients (15%) in the pretreated population having discontinued because of adverse events. The most commonly reported grade 3 adverse events and laboratory abnormalities were diarrhoea, hand-foot syndrome and decreased platelets in the first-line population, and fatigue and decreased neutrophils and platelets in the pretreated population. In particular, the incidence of grade 3/4 haematological toxicities such as decrease of neutrophils and platelets seems to be higher in this trial when compared with the previous worldwide data, more than 50% versus around 10%, respectively.
There were modest declines in health-related quality of life during the sunitinib treatment periods as measured by EQ-5D and EQ-VAS, which readily recovered during the subsequent off-treatment periods. In addition, overall scores were slightly lower at the end of treatment compared with baseline, and the data suggested a slight, non-significant trend towards higher scores in the pretreated over the firstline population.
Preclinical studies have demonstrated that sunitinib is effective at plasma concentrations 50 ng/ml (23) . In the current study, therapeutically effective levels of the drug were reached after 2 weeks of treatment during cycle 1, levels which, although cyclic, reflecting the dosing schedule, were sustained for the duration of treatment in both populations. Repeated dosing was not associated with accumulation of sunitinib in plasma.
Houk et al. (25) analysed merged data from 13 Western studies (including Japanese subjects in one study) and one Japanese study using a population-PK approach, and demonstrated that tumour type (i.e. metastatic RCC, gastrointestinal stromal tumours or other solid tumours) as a covariate contributed the largest effect on the PK of sunitinib and SU12662. Gender, body weight and ECOG PS score had less of an impact, and Japanese patients showed similar PK to Caucasians. They concluded that no starting sunitinib dose adjustments are recommended based on the magnitude of predicted changes owing to any covariate studied. Correlations between body weight and AUC values of sunitinib, SU12662 and total drug in Japanese and Caucasian subjects from the above 13 Western studies and one Japanese study were further investigated, and no clear correlations 
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Sunitinib in Japanese patients with metastatic RCC between the AUC values and body weight were identified in either population (Figure 4) . Importantly, although the body weights of Japanese subjects were generally lower when compared with those of Caucasian subjects, the AUC values seen in Japanese subjects were within the range of those seen in Caucasian subjects, indicating no substantial difference in the AUC of sunitinib, SU12662 or total drug between these two populations. The incidence of haematological adverse events was numerically higher in this trial with Japanese patients (n ¼ 51) compared with those previously reported for sunitinib in Western patients (n ¼ 375) (17) . Better understanding of the mechanisms underlying the side effects of sunitinib is of great interest and may help explain this difference. Since the AUC values of sunitinib and SU12662 were similar between Japanese and Caucasian subjects (Figure 4) , the likely disparities in the adverse event profiles may be explained by differences in the relative importance (e.g. expression levels and activity) of sunitinib-sensitive kinases that are involved in the homeostatic regulation of the haematopoietic system. However, given the small number of Japanese patients in this trial (n ¼ 51), it is still to be statistically determined whether substantial racial/ethnic differences exist in the pharmacological properties of sunitinib.
CONCLUSION
Sunitinib 50 mg administered on Schedule 4/2 is effective and well-tolerated for the treatment of Japanese patients with metastatic RCC in both the first-and second-line treatment settings. It is also of note that there was a trend towards a greater antitumour efficacy and higher incidence of haematological adverse events in Japanese patients compared with the mostly Western patients who participated in prior trials, warranting further investigation.
